Review papers with raw data transparency

1) Main claims and how the paper supports them

• Claim: CEBPa is up-regulated at the two-to-four-cell transition and later enriched in TE of blastocysts.
  Evidence: single-cell RT-qPCR and scRNA-seq datasets, immunofluorescence showing heterogenous four-cell expression and TE localization at blastocyst stage. CEBPa expression timing and localization
• Claim: NR5A2 regulates Cebpa during early ZGA.
  Evidence: public CUT&RUN/KO datasets showing NR5A2 binding to upstream Cebpa enhancers and NR5A2 KO silences Cebpa in 4/8 cell embryos. NR5A2 regulation of Cebpa
• Claim: CEBPa is functionally important for TE formation in vivo.
  Evidence: zygotic CRISPR-Cas9 KO with 90% KO efficiency; KO embryos show delayed morula-to-blastocyst transition and reduced TE markers (Tfap2c, Cdx2, Tead4, Gata3) and ~20% fewer CDX2+ TE cells at E4.5 while OCT4/ICM unaffected. CEBPa KO embryo phenotype
• Claim: Ectopic CEBPa activates TE program in ESCs (TELCs) and reveals a CEBPa regulome.
  Evidence: inducible CEBPa-ER in E14 ESCs activated TE TFs (Gata3, Tead4, Tfap2c, Eomes, Elf5, Id2) with time-resolved RNA-seq; cells acquired TE morphology and phagocytic function; ATAC-seq identified 9697 CEBPa-responsive sites; ChIP-seq found 30,507 CEBPa peaks at 24 hpi. CEBPa overexpression in ESCs and regulome
• Claim: A subset of CEBPa-regulated TE enhancers is already accessible or primed in 4–8 cell embryos.
  Evidence: intersection with published embryo ATAC/H3K27ac shows 9/16 TE-GREs accessible at 4/8 cell stages; +21 kb Tead4 TE-GRE active in 4–8 cell embryos; +12 kb Elf5 TE-GRE primed. Embryonic accessibility of TE-GREs

2) Strengths

• Multimodal, orthogonal dataset: in vivo embryo manipulations, zygotic CRISPR KO, inducible ESC model, bulk and single-cell RNA/ATAC, ChIP-seq, motif analyses—strengthens causal inference by converging evidence Study multimodality
• Time-resolved experiments (0,12,24,48,72 hpi) and dose separation (SSEA-1 low vs high) clarify kinetics and dose dependence of CEBPa action Time and dose resolved experiments
• Integration with published embryonic ATAC/H3K27ac datasets provides in vivo relevance to ESC-derived regulome findings Integration with embryo datasets

3) Limitations, gaps, and alternative interpretations

1. No direct in vivo CEBPa binding data at 4–8 cell embryos — major caveat: the key mechanistic link (CEBPa physically binding and activating the same enhancers in actual 4–8 cell blastomeres) is inferred by overlap of ESC ChIP/ATAC and embryo ATAC/H3K27ac rather than demonstrated by CEBPa ChIP or CUT&RUN in 4–8 cell embryos. This is acknowledged by the authors as requiring definitive proof Need for in vivo binding evidence
2. CRISPR KO specificity and mosaicism — zygotic CRISPR yields high efficiency (90%) but may generate mosaic alleles and off-target edits; functional partial penetrance (subset of embryos delayed) and heterogeneity in KO effects are reported. Paper reports 28/32 embryos with reduced CEBPa but does not fully profile off-targets or transcriptome-wide compensation. This weakens a purely loss-of-function causal claim unless complemented by rescue experiments (e.g., mRNA rescue or conditional KO restricted to early blastomeres) CRISPR KO caveats
3. ESC overexpression model limitations — ectopic induction in ESCs is an artificial system and may create nonphysiologic TF concentrations and binding patterns (pioneer factors can bind many sites when highly expressed). The study partially addresses dose by separating SSEA-1 low/high cells and showing dose-dependence, yet overexpression might reveal latent binding not used in embryos. Therefore the mapping from induced ESC regulome to embryo physiology is plausible but not definitive ESC overexpression limitations
4. Small human embryo sample — human data are limited to 3 warmed blastocysts; authors note evolutionary differences in timing of ZGA and expression; extrapolation to human TE priming is therefore speculative and needs more samples and direct assays Limited human embryo data
5. Functional hierarchy unresolved — CEBPa appears to prime TE enhancers including those near Tead4/Gata3/Cdx2, but the order-of-action and dependence among TE TFs (CEBPa vs TEAD4 vs NR5A2 vs TFAP2C etc.) still needs mechanistic dissection (eg epistasis/rescue experiments). The authors propose NR5A2 upstream of Cebpa and TEAD factors downstream or cooperating, but the regulatory circuitry needs more causal tests beyond correlations and motif co-enrichment Regulatory hierarchy uncertainties

4) Experimental robustness and reproducibility

Overall experimental design is rigorous: authors provide replicates for RNA/ATAC/ChIP (biological duplicates), time series, sorted fractions, and single-cell multiomics (thousands of cells per condition). Methods and software are standard (Seurat, Signac, Harmony, MACS2, diffBind, chromVAR), which supports reproducibility provided raw data and pipelines are deposited. The paper states data availability and references public embryo ATAC datasets (GEO etc). However, the excerpt does not list explicit GEO accession numbers for all generated datasets; for full reproducibility the community will require public deposition of the raw fastqs, processed matrices, ChIP-seq bigwigs, and the code notebooks used for analyses (the methods mention standard tools). The authors used appropriate controls (uninduced ESCs, TSCs) and included multiple orthogonal assays, strengthening reproducibility prospects Reproducibility assessment

5) Plausible alternative hypotheses and falsification tests

• Alternative: CEBPa is not the physiological initiator but a permissive pioneer that, when ectopically expressed, can create TE identity; early embryo TE priming might instead be driven primarily by NR5A2/TEAD4 and co-factors, with CEBPa a secondary enabler. Test: perform zygote-stage rescue by expressing Cebpa in NR5A2 KO embryos to see if Cebpa restores TE enhancer accessibility and TE gene expression (epistasis test) NR5A2 versus CEBPa epistasis
• Falsification: If Cebpa zygotic KO embryos showed normal TE formation and no change in TE-GRE accessibility or TE TF expression in fully penetrant studies, the central claim would be undermined. The paper reports only partial penetrance/delay, so stronger conditional deletion (maternal zygotic or targeted outer-cell KO) with comprehensive single-embryo ATAC/RNA profiling would be decisive How to falsify in vivo claims

6) Practical implications and suggested next experiments (testable, concrete)

1. Direct in vivo binding: perform low-input CUT&RUN or CUT&Tag for CEBPa on pools of 4–8 cell embryos (or single-embryo indexed CUT&Tag) to test whether the TE-GREs identified in ESCs are directly bound by CEBPa in embryos. This directly addresses the paper's key acknowledged gap Need for embryo CUT&Tag
2. Epistasis: rescue NR5A2 KO embryos by expressing Cebpa to test whether CEBPa is sufficient downstream of NR5A2 to restore TE enhancer accessibility and TE TF expression. Conversely, NR5A2 rescue in Cebpa KO would test ordering. These are decisive genetic hierarchy experiments.
3. Conditional outer cell KO: use trophectoderm-specific Cre (or Tat-Cre trophectoderm targeting) to delete Cebpa selectively in outer cells while leaving inner cells intact; assay TE formation and enhancer accessibility—this avoids zygotic mosaicism and clarifies tissue-autonomous roles Tat-Cre trophectoderm editing method
4. Single embryo multiomic KO profiling: perform single-embryo scRNA+scATAC from Cebpa KO and controls at 4, 8 cell and morula to directly measure consequences on enhancer accessibility and gene expression in the same embryos.

7) Short checklist for readers who want to reuse or extend the work

• Request the raw sequencing fastqs, ChIP bigwigs, and code notebooks from the authors or from the paper data repository (GEO/SRA) to reproduce peak calling and integration steps; verify MACS2, diffBind, and chromVAR parameters.
• For embryo CUT&Tag/CUT&RUN targetting CEBPa, pool embryos carefully (biological replicates) and use spike-in controls for normalization; validate antibodies for low-input chromatin assays.
• Use conditional genetic tools (trophectoderm-specific delivery/Cre) to avoid mosaic zygotic editing and to test tissue autonomy.

8) Quick quantitative summary of core data points (as reported)

9) Final critical synthesis

The paper presents a coherent, well-executed body of work that converges multiple experimental modalities to support the novel and plausible model: CEBPa functions early to install TE competence through chromatin priming of TE enhancers, acting as both a direct pioneer and indirect chromatin remodeler (via enabling other TE TFs). The experimental strengths (time series, dose separation, single-cell multiomics) outweigh caveats, but the central mechanistic gap remains the lack of direct demonstration that CEBPa binds the same enhancers in 4–8 cell embryos in vivo and that such binding is necessary and sufficient for TE competence in the embryonic context. Addressing this with embryo CUT&RUN/CUT&Tag and conditional rescue/epistasis experiments would transform a strong correlational/inductive case into a near-definitive causal model. Confidence in the core conclusion (CEBPa contributes to early TE competence) is moderate-high based on presented evidence, but full mechanistic certainty requires the additional embryo-level binding and rescue tests described above Overall assessment and next steps

10) Tools and datasets to reproduce or extend the analysis

• Suggested datasets: raw scRNA/scATAC fastqs from the paper, embryonic ATAC H3K27ac public sets referenced in the manuscript (eg GSE145609 integration dataset), CEBPa ChIP-seq bigwigs at 24 hpi. The authors cite public embryo ATAC resources (used for 4–8 cell mapping) and standard tools: Harmony, Seurat, Signac, chromVAR (see methods) Methods and referenced datasets